Document Detail


Fluoride ion toxicity in human kidney collecting duct cells.
MedLine Citation:
PMID:  8602675     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Several halogenated anesthetics induce a urinary concentrating defect, partly related to fluoride ion toxicity in collecting duct cells. The aim of this study was to investigate the effects of fluoride ion in human kidney cells. METHODS: Immortalized human collecting duct cells were used. In a first set of experiments, the toxicity threshold concentration was determined by exposing cell cultures for 24 h to increasing concentrations of fluoride ion in the medium: 0, 1, 5, and 10 mM. The second set of experiments was a time- effect study in which cells were exposed to 5 mM fluoride for 2, 6, and 24 h. Assessment of toxicity was based on several endpoints: cell number, protein content, (3)H-leucine incorporation in newly synthesized proteins, extracellularly released lactate dehydrogenase, Na-K-ATPase pump activity, and electron microscope studies. RESULTS: After 24 h of exposure, fluoride ion decreased cell number (-23%, P<0.05), total protein content (-30%, P<0.05) and increased lactate dehydrogenase release (+236%, P<0.05) at a threshold concentration of 5mM. Fluoride ion also inhibited Na-K- ATPase activity at 5 mM (-58%, P<0.05). Major morphologic alterations of mitochondria, including crystal formation, were detected from 1 mM fluoride concentration. Time-effect studies showed that, after only 6 h of exposure at 5 mM, fluoride decreased cell number (-13%, P<0.05), (3)H-leucine incorporation (-48%, P<0.05), and Na-K-ATPase activity (- 20%, P<0.05) and increased lactate dehydrogenase release (+145%, P<0.05). Crystal deposits in mitochondria again were a more sensitive marker of cell injury, detectable after only 2 h of exposure. CONCLUSIONS: these results suggest that the mitochondrion is a target of fluoride toxicity in human collecting duct cells, and its alteration is partly responsible for the sodium and water disturbances observed in patients.
Authors:
M L Cittanova; B Lelongt; M C Verpont; M Geniteau-Legendre; F Wahbe; D Prie; P Coriat; P M Ronco
Related Documents :
10475265 - In vitro analysis of venom from the wasp nasonia vitripennis: susceptibility of differe...
6889485 - Comparative kinetics of poly(6-thioinosinic acid) and 6-mercaptopurine treated l1210 ce...
9438145 - Secretion of a urodilatin-like immunoreactive (uro-like-ir) substance from a human kidn...
8983945 - Regulatory volume increase of human non-pigmented ciliary epithelial cells.
22393165 - Agaricus bisporus lectins mediates islet β-cell proliferation through regulation of ce...
22131645 - Phase toxicity of dodecane on the microalga dunaliella salina.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anesthesiology     Volume:  84     ISSN:  0003-3022     ISO Abbreviation:  Anesthesiology     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1996-05-08     Completed Date:  1996-05-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1300217     Medline TA:  Anesthesiology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  428-35     Citation Subset:  AIM; IM    
Affiliation:
Departement d'Anesthesie-Reanimation, Hopital Pitie-Salpetriere, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anesthetics, Inhalation / toxicity*
Cell Survival / drug effects
Cells, Cultured
Dose-Response Relationship, Drug
Fluorides / toxicity*
Humans
Kidney Tubules, Collecting / drug effects*,  enzymology,  ultrastructure
Microscopy, Electron
Mitochondria / drug effects,  ultrastructure
Sodium-Potassium-Exchanging ATPase / metabolism
Chemical
Reg. No./Substance:
0/Anesthetics, Inhalation; 0/Fluorides; EC 3.6.3.9/Sodium-Potassium-Exchanging ATPase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quantitation of depth of thiopental anesthesia in the rat.
Next Document:  Theoretical assessment of normobaric oxygen therapy to treat pneumocephalus.